EGI.L Regulatory News (EGI)

16 March 2015

Electrical Geodesics, Inc

Result of Special Meeting

EUGENE, OREGON, US, 16 March 2015 - Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, is pleased to announce that at the Special Meeting held today at 9.00 a.m. US Pacific time, the proposed resolution in connection with the Placing announced by the Company on 6 March 2015, was duly passed.

Accordingly, the Company has applied to the London Stock Exchange for 3,076,923 new Common Shares to be admitted to trading on AIM ("Admission") on the $0.001 Reg S restricted line (ISIN: USU2830P2021, TIDM: EGI). It is expected that Admission will occur at 8.00 a.m. on 17 March 2015.

Following admission of the 3,076,923 new Ordinary Shares to trading on AIM, the total number of Common Shares with voting rights in issue will be 27,525,709 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Upon Admission, the new Common Shares will be issued, credited as fully paid and will rank pari passu in all respects with the existing Common Shares of the Company.

For more information contact:

Electrical Geodesics, Inc. in Summary

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic and neuromodulation products used to monitor, interpret and modulate brain activity, based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

EGI's dEEG systems, available in the GES 300 and now the GES 400 lines, capitalise on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).

See our website www.egi.com

Glossary